Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies.

Background: T-cell malignancies are highly aggressive hematological tumors with limited effective treatment options. CAR-NK cell therapy targeting CD7 has emerged as a promising approach for treating T-cell malignancies. However, conventional CAR-NK cell therapy faces the challenges of cell fratricide due to CD7 expression on both malignant cells and normal NK cells.

Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals.

Background: Chimeric antigen receptor (CAR) engineered natural killer (NK) cells exhibit advantages such as MHC-independent recognition and strong anti-tumor functions. However, allogeneic CAR-NK cells derived from human tissues are heterogeneous and susceptible to clearance by hosts.

Methods: We generated a B2M knockout, HLA-E and CD19 CAR ectopic expressing embryonic stem cell (ESC) line, which differentiated normally and gave rise to homogeneous CD19 CAR-NK (CD19 CAR-UiNK) cells using an organoid aggregate induction method.

Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity.

Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is emerging as a promising cancer treatment, with notable safety and source diversity benefits over CAR-T cells. This study focused on optimizing CAR constructs for NK cells to maximize their therapeutic potential. We designed seven CD19 CAR constructs and expressed them in NK cells using a retroviral system, assessing their tumour-killing efficacy and persistence.

Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy.

Purpose: CD7 chimeric antigen receptor T (CAR-T) therapy has potent antitumor activity against relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), however, immune reconstitution after CAR-T remains largely unknown.

Patients And Methods: An open-label phase I clinical trial (ChiCTR2200058969) was initiated to evaluate safety and efficacy of donor-derived CD7 CAR-T cells in 7 R/R T-ALL/LBL patients. CAR-T cells were detected by flow cytometry and PCR.

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy.

Hematological malignancies are one of the most lethal illnesses that seriously threaten human life and health. Lipids are important constituents of various biological membranes and substances for energy storage and cell signaling. Furthermore, lipids are critical in the normal physiological activities of cells.

Electrospun PEGylated PLGA nanofibers for drug encapsulation and release.

We report the fabrication of electrospun nanofibers of polyethylene glycol (PEG)-modified poly (lactic-co-glycolic acid) (PLGA) with a fast release profile for biomedical applications. In this work, PLGA was first covalently modified with methoxy poly (ethylene glycol) amine (mPEG-NH). The formed PEGylated PLGA (PLGA-PEG) was then mixed with a model drug amoxicillin (AMX) for subsequent fabrication of drug-loaded electrospun nanofibers.

[Effects of taurine on alterations in structure and function of sternohyoid muscle in metabolic syndrome rats].

Objective: To investigate the alterations in structure and function of sternohyoid muscle of metabolic syndrome (MS) rats effects and the effects of taurine thereupon contractile properties.

Methods: Twenty-one healthy male SD rats were randomly assigned to three groups: control group (Group A, n=6) fed with normal food, MS group (Group B, n=8) fed with high-lipid forage for 9 weeks to induce MS and then fed with the same high-lipid forage for 12 weeks in addition, and taurine group (Group C, n=7), fed with high-lipid forage for 20 weeks and given gastric perfusion of taurine 50 mg x d(-1) x kg(-1) since the tenth week for 12 weeks. Venous blood samples were collected to undergo biochemical examination of plasma total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and glucose (Glu).